Phase III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging in Patients With Prostate Cancer With Rising PSA Levels [Biochemical Recurrence (BCR)]
Latest Information Update: 13 Feb 2024
At a glance
- Drugs 18F-CTT 1057 (Primary) ; Gallium (68Ga) gozetotide
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use; Registrational
- Acronyms GuidePath
- Sponsors Novartis; Novartis Pharmaceuticals
- 05 Feb 2024 Status changed from active, no longer recruiting to completed.
- 10 Dec 2023 This trial has been completed in France according to European Clinical Trials Database record.
- 17 Nov 2023 Planned End Date changed from 6 Nov 2023 to 23 Nov 2023.